正在加载公司
ONCBeone Medicines Ltd.US$47.6BA+Just reported
From Coya Therapeutics's results release of 2026年11月10日; its quarterly report has since been filed.
Actual
US$234.1K
-93% y/y
-3.9% q/q
Guided
—
No guide given
Actual
-US$0.45
Guided
—
No guide given
Actual
-US$10.9M
Guided
—
No guide given
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
基于 Coya Therapeutics, Inc. 自己向美国证券交易委员会（SEC）提交的申报文件。数字如实呈报，每股历史已重述到今天的股数口径。 这是对一门生意的描述——不是投资建议，也不是买卖任何证券的推荐。
The themes Coya Therapeutics is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Graded A or B and worth $2B or more: A first, then the largest.
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
US$3.12-3.4%11月13日 收盘
数据截至2026年9月30日，来自2026年11月10日提交的10-Q
Grade F-
价格下方的色带显示每个日期的评级，仅依据当时已公开的文件计算。
显示 Coya Therapeutics, Inc. 评级历史 12 个季度中的 2 个。 其余 10 个可回溯到 2024年3月。
